170 related articles for article (PubMed ID: 8841099)
1. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
2. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
3. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
5. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
6. Serum beta 2 microglobulin in multiple myeloma and related plasma cell dyscrasias.
Pasquini E; Tiraferri E; Fattori PP; Fabbri I; Gobbi M
Haematologica; 1987; 72(1):17-21. PubMed ID: 3108090
[No Abstract] [Full Text] [Related]
7. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
8. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma.
Schaar CG; Kaiser U; Snijder S; Ong F; Hermans J; Franck PF; Kluin-Nelemans JC
Br J Haematol; 1999 Oct; 107(1):132-8. PubMed ID: 10520033
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
11. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
12. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma.
Ong F; Hermans J; Noordijk EM; De Kieviet W; Seelen PJ; Wijermans PW; Kluin-Nelemans JC
Leuk Lymphoma; 1997 Nov; 27(5-6):495-501. PubMed ID: 9477131
[TBL] [Abstract][Full Text] [Related]
13. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
14. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
15. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
17. Are serum interleukin-6 levels always useful for differentiating monoclonal gammopathies in unselected patients?
Greco C; Vitelli G; Cianciulli AM; Alvino S; Gandolfo GM; Ameglio F
Blood; 1992 Apr; 79(8):2173-4. PubMed ID: 1562744
[No Abstract] [Full Text] [Related]
18. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
19. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
20. Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma.
Perosa F; Prete M; Luccarelli G; Dammacco F
Br J Haematol; 2003 Jan; 120(1):36-43. PubMed ID: 12492574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
